Boehringer Ingelheim is a global pharmaceutical company based in Ingelheim am Rhein, Germany, with a focus on improving patient care through innovation. Established in 2010, the Boehringer Ingelheim Venture Fund specializes in early-stage investments in life sciences, biotechnology, and digital health. The fund targets groundbreaking therapeutics and novel technologies, emphasizing areas such as immuno-oncology, regenerative medicine, and disease-related biomarkers. It typically invests up to €15 million over the lifetime of a company, with a specific focus on North America and Europe/Israel. Boehringer Ingelheim's commitment to advancing biomedical research aims to enhance patient outcomes through pioneering science and the development of new therapeutic concepts.
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology.
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions.
Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
Operator of a pioneering private biotech company intended for vivo direct cell reprogramming for cancer immunotherapy. The company's proprietary reprogramming technologies develop gene therapy products that ignite efficient and personalized immune responses to establish a robust pipeline of off-the-shelf cancer immunotherapies, activating personalized anti-cancer immune defenses for the benefit of patients in need by offering new treatment avenues for cancers resistant to conventional methods, enabling patients to acquire new forms of treatment for cancer resistant to conventional treatment methods.
Optina Diagnostics Inc. develops a technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Its Optina Diagnostic retinal imaging test serves the healthcare industry. The company was founded in 2010 and is headquartered in Montréal, Canada.
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
Abexxa Biologics is a biopharmaceutical company that focuses on discovering and developing breakthrough antibody-based drugs designed to revolutionize cancer treatments by providing highly effective targeted therapies. Its mission is to develop products that revolutionize the treatment of cancer through activation of the immune cells to destroy the tumor.
The company was founded in 2015 and is headquartered in Arlington, Texas.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
Dopavision GmbH develops a digital drug that treats myopia by targeting the neurotransmitter cascade and regulates the size of the eyeball. The company was founded in 2017 and is based in Berlin, Germany.
xCures, Inc. is a company based in Los Altos, California, founded in 2018, that focuses on enhancing cancer treatment through an AI-based precision oncology platform. This platform addresses the shortcomings of traditional drug-centric approaches by integrating cancer research and clinical care, running a perpetual trial that captures Real World Evidence (RWE). By continuously learning from patient data across various treatments, xCures coordinates treatment recommendations tailored to individual needs. The software supports advanced cancer patients and their healthcare providers by structuring insights from tumor boards and utilizing machine learning to identify the most effective treatment options. Ultimately, xCures aims to reduce the time and cost associated with drug development, thereby improving patient outcomes in oncology.
Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
LABOR DR. MERK & KOLLEGEN GMBH was founded in 1971 with the goal of developing and producing high quality diagnostics for medical use. Over the years, they gained extensive knowledge in biotechnology, virology, microbiology and toxicology and provide this know-how to external parties. They hold excellent expertise in biosafety testing of products from pharmaceutical industries or medical device manufacturers. Especially in the fields of virological and microbiological testing a wide range of GMP and GLP compliant methods for preclinical studies or quality control of final products are available. Our highly qualified and experienced team will provide personal consultation during study design and test performance, and they guarantee an economical and reliable solution to our customers’ needs.
Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digital therapeutics. A digital solution that is just as effective as a drug. But without side effects.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
Ruipeng Pet Hospital, located in Shenzhen, specializes in a comprehensive range of pet care services. The hospital provides medical and beauty care for pets, including healthcare, foster care, bathing, SPA treatments, grooming, food, and entertainment. By offering both digital and clinical services, Ruipeng aims to ensure that pet owners can access high-quality care for their animals efficiently. The organization also includes online shopping options to further support pet owners in meeting their pets' needs.
Libra Therapeutics, Inc. operates as a biotechnology company that develops novel disease-modifying therapeutics and drug candidates for restoring the cellular balance disrupted in neurodegenerative diseases. The company’s therapeutic platform discovers and develops small molecule drugs to attenuate the production of neurotoxic proteins for the treatment of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease. The company was founded in 2019 and is based in San Diego, California.
Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.
Aignostics GmbH, founded in 2018 and based in Berlin, Germany, specializes in AI-powered diagnostics and pathology software solutions aimed at enhancing pharmaceutical research and clinical diagnostics. The company focuses on precision diagnostics by utilizing its patented technology to provide explainable AI that addresses the limitations of traditional AI systems. Aignostics' platform generates precise heatmaps and image overlays that facilitate the interpretation of diagnostic results, allowing pathologists to quickly verify findings. This capability is essential for ensuring accurate diagnoses, particularly in the context of drug development and the discovery of tissue-based biomarkers for complex diseases like cancer. By improving the understanding of pathology, Aignostics supports more effective diagnoses and treatments in the medical field.
Bodyport Inc. manufactures sensor fitted weighing scales for cardiac patients. It offers Bodyport, a biomarker-driven virtual clinic for the prevention and management of heart disease. Its device measures blood pressure, heart rate, heart rate variability, arterial stiffness, and health assessment through a person’s feet. The company also provides online patient portal and educational materials. The company was incorporated in 2015 and is based in San Francisco, California.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of bacteria-based therapies specifically designed for cancer treatment. Recognizing the ongoing need for innovative solutions in oncology, T3 Pharmaceuticals aims to enhance the lives of cancer patients by creating highly specific and efficient treatments using live bacteria. Through its work, the company seeks to address the limitations of conventional therapies and contribute to the advancement of novel cancer medicines.
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
Northern Biologics Inc. is an early-stage biologics company focused on developing antibody-based therapeutics for oncology and fibrosis. Founded in 2014 and based in Toronto, Canada, the company utilizes a cutting-edge phage display platform for antibody discovery, which has been developed by leading researchers at the University of Toronto. Northern Biologics aims to address novel and challenging targets by creating innovative functional modulators of key signaling pathways involved in cancer and fibrosis. The company has established a strategic collaboration with Celgene Corporation and operates as a subsidiary of Boehringer Ingelheim International GmbH as of May 2020.
Wellth develops and operates a mobile application to lower cost for payors and rewards for consumers. Its application engages consumers through providing targeted incentive plans, delivering reminders and information, and sharing cost savings that help them build healthy habits and foster disease management. It focuses on reducing the cost of the healthcare system by encouraging consumers to manage their diseases and to take preventative actions to stay healthy. Wellth is based in New York, New York.
Actym is a biotechnology company that focuses on developing an immuno-oncology platform. It specializes in the fields of medical device, manufacturing, and distribution. It focuses on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor.
It was founded in 2017 and headquartered in San Francisco, California.
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.
It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, focused on developing innovative drugs for the treatment of acute and chronic liver diseases. Founded in 2016, the company’s therapeutic approach is centered on a proprietary molecular target known as Mitogen-Activated Protein (MAP) Kinase 4. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen highlighted MKK4 as a crucial regulator of liver regeneration. Their findings indicated that small RNA molecules could suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely affected livers. HepaRegeniX is specifically working on small-molecule inhibitors of MKK4, with potential applications in treating conditions such as nonalcoholic steatohepatitis.
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.
ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.
The company intends to use the funds to advance its arenavirus-based lead candidates towards clinical testing. They will develop the initial product candidates using its proprietary Fast Evolution platform, which will generate virus strains with optimized anti-tumoral properties. These candidates will be selected based on their ability to re-program the immune system to specifically and efficiently eliminate the malignant tumor tissue.
T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of bacteria-based therapies specifically designed for cancer treatment. Recognizing the ongoing need for innovative solutions in oncology, T3 Pharmaceuticals aims to enhance the lives of cancer patients by creating highly specific and efficient treatments using live bacteria. Through its work, the company seeks to address the limitations of conventional therapies and contribute to the advancement of novel cancer medicines.
Tacalyx GmbH operates as an oncology company, which focuses on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. It provides technology platform for TACAs as novel targets for cancer therapy. The company is based in Berlin, Germany.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
Dopavision GmbH develops a digital drug that treats myopia by targeting the neurotransmitter cascade and regulates the size of the eyeball. The company was founded in 2017 and is based in Berlin, Germany.
OncoMyx Therapeutics, Inc. is a biotechnology company specializing in the development of oncolytic immunotherapies utilizing the myxoma virus (MYXV) to stimulate immune responses against cancer. Founded in 2018 and based in Phoenix, Arizona, the company focuses on targeting both hematologic and solid tumors through its innovative MYXV platform. This platform employs a novel systemic delivery method that allows the myxoma virus to be carried by human leukocytes, enabling it to effectively infect tumor cells. By assembling a highly skilled team in oncolytic virus research, OncoMyx aims to advance a pipeline of therapeutic options designed to improve outcomes for cancer patients.
Rinri Therapeutics is a provider of private biotechnology services intended to develop advanced regenerative stem cell-based therapies for the treatment of hearing loss. The company's stem cell technology replaces damaged or dead sensory cells of the inner ear, enabling doctors to restore hearing of patients.
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
ICD Therapeutics
Acquisition in 2019
ICD Therapeutics is a privately held MacroDel biologics-delivery platform developer.
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
Wellth develops and operates a mobile application to lower cost for payors and rewards for consumers. Its application engages consumers through providing targeted incentive plans, delivering reminders and information, and sharing cost savings that help them build healthy habits and foster disease management. It focuses on reducing the cost of the healthcare system by encouraging consumers to manage their diseases and to take preventative actions to stay healthy. Wellth is based in New York, New York.
MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
Acousia Therapeutics GmbH is a biotech company that specializes in identifying small molecules for the treatment of hearing loss. It develops drugs for local application, which protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons, such as noise trauma, treatment with ototoxic drugs, or sudden deafness. The company was founded in 2012 and is based in Tubingen, Germany.
Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions.
Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medical practitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Aelin Therapeutics NV is a Belgian biotherapeutics company founded in 2017, focused on developing antibiotics and therapeutics utilizing its innovative Pept-in technology. This technology leverages protein aggregation to achieve functional knockdown of target proteins, making it applicable against challenging conditions such as Methicillin-resistant Staphylococcus aureus (MRSA) and other undruggable targets in humans. Aelin Therapeutics was established as a collaboration between VIB and partner universities including KU Leuven, VUB, and UGent, building on the pioneering research of noted structural biologists. The company has compiled a robust preclinical proof of concept data package, demonstrating the diverse applications of its technology across various biological targets, including bacteria, cancer cells, fungi, viruses, and plant cells. Aelin Therapeutics differentiates itself through the unique mechanism of action of its Pept-in technology, which allows for the rational design of biotherapeutics that can target intracellular spaces often inaccessible to conventional small molecules or antibodies. The company is headquartered in Heverlee, Belgium.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.
Topas Therapeutics GmbH is a biotechnology company based in Hamburg, Germany, that specializes in developing nanoparticle-based therapeutics aimed at treating autoimmune diseases, allergies, and anti-drug antibodies. Founded in 2013, the company utilizes its proprietary Topas Particle Conjugates technology platform to induce antigen-specific immune tolerance by leveraging the liver's natural immunological processes. Topas has a clinical-stage pipeline that includes its lead product candidate, TPM203, which is currently being tested for pemphigus vulgaris, along with other programs targeting conditions such as celiac disease, Type 1 diabetes, and multiple sclerosis. The company has established research partnerships with major pharmaceutical firms, including Eli Lilly and Boehringer Ingelheim, to advance its mission of addressing significant unmet medical needs.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, which is the leading cause of death in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor designed to target a critical microRNA that regulates harmful changes in the heart resulting from stress or injury. Cardior Pharmaceuticals is positioned as a planned academic spin-off, emphasizing innovative approaches to address significant cardiovascular health challenges.
ImCheck Therapeutics SAS is a biotechnology company incorporated in 2015 and based in Marseille, France. The company specializes in designing and developing immunotherapeutics that target the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. With a primary focus on immuno-oncology, ImCheck Therapeutics develops immunomodulatory antibodies aimed at treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company is dedicated to addressing severe unmet medical needs through its innovative approach to cancer treatment and the development of next-generation immunotherapeutics.
Sentien Biotechnologies, Inc. develops proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions, a combinational mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repairing response. The company was founded in 2008 and is headquartered in Medford, Massachusetts.
Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include Sentieon DNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation.
The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California.
HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, focused on developing innovative drugs for the treatment of acute and chronic liver diseases. Founded in 2016, the company’s therapeutic approach is centered on a proprietary molecular target known as Mitogen-Activated Protein (MAP) Kinase 4. Research conducted by Professor Lars Zender and his team at the University Hospital Tübingen highlighted MKK4 as a crucial regulator of liver regeneration. Their findings indicated that small RNA molecules could suppress MKK4 gene expression, thereby restoring the regenerative capacity of hepatocytes even in severely affected livers. HepaRegeniX is specifically working on small-molecule inhibitors of MKK4, with potential applications in treating conditions such as nonalcoholic steatohepatitis.
Acousia Therapeutics GmbH is a biotech company that specializes in identifying small molecules for the treatment of hearing loss. It develops drugs for local application, which protect hearing function or restore hearing in patients who have lost their hearing ability due to various reasons, such as noise trauma, treatment with ototoxic drugs, or sudden deafness. The company was founded in 2012 and is based in Tubingen, Germany.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Metabomed is a drug discovery company focused on developing treatments for cancer by targeting the unique metabolic pathways of cancer cells. Utilizing a proprietary platform that integrates computational biology, genomics, and metabolomics, Metabomed identifies specific metabolic alterations associated with cancer growth. The company's small molecule drugs are designed to halt the proliferation of reprogrammed cancer cells, which allows oncologists to initiate treatment more swiftly and enhances the chances of successful patient outcomes while minimizing harm to healthy tissues. Through its innovative approach, Metabomed aims to advance cancer treatment by addressing the metabolic characteristics that distinguish cancer cells from normal cells.
Amal Therapeutics SA, a biotech company, engages in the research and development of therapeutic vaccines in oncology. It uses its cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology, including cancer vaccines, immunotherapy, and therapeutic cancer vaccines. The company was founded in 2012 and is based in Geneva, Switzerland. As of July 15, 2019, Amal Therapeutics SA operates as a subsidiary of Boehringer Ingelheim GmbH.
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
Rigontec GmbH is a biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. The company develops ImOl100, a compound stimulating the immune receptor retinoic acid-inducible gene I, which recognizes viral RNA. Its ImOl100 is also a minimal mimic of naturally occurring 3pRNA, a motif typically occurring in viral RNAs. The company’s compounds avoid the pitfalls of cancer vaccines, checkpoint inhibitors, and therapeutics based on the identification of tumor antigens. Rigontec GmbH was founded in 2014 and is based in Planegg, Germany. As of October 26, 2017, Rigontec GmbH operates as a subsidiary of Merck & Co., Inc.
Hookipa Pharma is a clinical-stage biopharmaceutical company focused on developing immune-therapeutics for infectious diseases and cancers using its proprietary arenavirus vector platforms. The company operates two main platforms: Vaxwave, aimed at creating prophylactic vaccines, and TheraT, which focuses on immuno-oncology therapies. Its key product candidates include HB-101, a vaccine for cytomegalovirus currently in a Phase II clinical trial for kidney transplant patients, and HB-201 and HB-202, which are in preclinical studies for treating human papillomavirus-positive cancers. Additionally, Hookipa is collaborating with Gilead Sciences to develop therapies for chronic Hepatitis B and HIV infections. Founded in 2011 and based in New York, Hookipa Pharma aims to leverage its innovative technologies to elicit robust immune responses, addressing limitations found in conventional vaccine and therapeutic approaches.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Eyevensys S.A.S. develops non-viral gene therapy treatments for ophthalmology. The company’s develops Electro-Transfection (ET) of plasmids to the ciliary muscle therapy to deliver calibrated and sustained therapeutic proteins preferentially in the vitreous for several months. It develops an Electro-Transfection Injection System (ETIS) which is a drug device solution consisting of a device and a pulse generator. The company focuses on Uveitis, age-related macular degeneration (AMD), and retinopathies, including Central Retinal Vein Occlusion (RVO) and Diabetic Retinopathy (DR/DME). Eyevensys S.A.S. was incorporated in 2008 and is based in Paris, France.
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
ArmaGen, Inc. is a clinical stage biotechnology company that develops therapies to treat severe neurological diseases. The company focuses on therapies for lysosomal storage, hunter syndrome, hurler syndrome, Sanfilippo A syndrome, metachromatic leukodystrophy, and neurodegenerative diseases. Its product candidates include AGT-182 for hunter syndrome; and AGT-181 for hurler syndrome. The company was formerly known as ArmaGen Technologies, Inc. ArmaGen, Inc. was incorporated in 2001 and is headquartered in San Diego, California.
Funxional Therapeutics Ltd. develops pharmaceutical products in the United Kingdom. Its product candidates include BN83470 for the treatment of respiratory indications, initially asthma; BN83250 for the prevention of surgical adhesion formation and for the treatment of stroke; and FX125L, an orally available small molecule that belongs to a therapeutic class named broad spectrum chemokine inhibitors. The company also offers early stage preclinical programs that focus on Alzheimer's disease, autoimmune disorders, and pain and diabetes. Funxional Therapeutics Ltd. as founded in 2005 and is based in Cambridge, the United Kingdom.
Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.
Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.
International Diagnostic Technology
Acquisition in 1978
International Diagnostic Technology is a manufacturer of diagnostic kits for food safety, and for drugs of abuse in dogs and horses. It was established in St. Joseph, Michigan.